SCHEMBL21318406

SCHEMBL21318406

CC(=O)c1ccc2c(c1)N(CC(C)CN(C)C)c1ccccc1S2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 8/20 0.70
ADRA1A P35348 8/20 0.70
DRD3 P35462 8/20 0.70
KCNH2 Q12809 8/20 0.70
CHRM2 P08172 7/20 0.70
CHRM1 P11229 7/20 0.70
OPRM1 P35372 6/20 0.70
ADRA2A P08913 6/20 0.70
DRD1 P21728 6/20 0.70
SLC6A2 P23975 6/20 0.70
SLC6A4 P31645 6/20 0.70
SLC6A3 Q01959 5/20 0.70
TBXA2R P21731 4/20 0.70
HRH3 Q9Y5N1 2/20 0.70
ABCB11 O95342 1/20 0.70
GFER P55789 2/20 0.68
CYP2D6 P10635 8/20 0.67
LMNA P02545 7/20 0.65
CYP1A2 P05177 5/20 0.65
DRD2 P14416 5/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aceprometazine SCHEMBL142393 0.86 HTR1A (0.79) HTR1AADRA1ADRD3KCNH2CHRM2
Aceprometazine SCHEMBL29497450 0.86 HTR1A (0.79) HTR1AADRA1ADRD3KCNH2CHRM2
Aceprometazine SCHEMBL11491734 0.86 HTR1A (0.79) HTR1AADRA1ADRD3KCNH2CHRM2
Aceprometazine SCHEMBL29688253 0.86 HTR1A (0.79) HTR1AADRA1ADRD3KCNH2CHRM2
SCHEMBL11884942 0.85 CYP2D6 (0.62) HTR1AADRA1ADRD3KCNH2CHRM2
Methylpromazine SCHEMBL29354434 0.84 CHRM2 (1.00) HTR1AADRA1ADRD3KCNH2CHRM2
Methylpromazine SCHEMBL18994 0.84 CHRM2 (1.00) HTR1AADRA1ADRD3KCNH2CHRM2
Methylpromazine SCHEMBL18993 0.84 CHRM2 (1.00) HTR1AADRA1ADRD3KCNH2CHRM2
Methylpromazine SCHEMBL21293802 0.83 GFER (0.82) HTR1AADRA1ADRD3KCNH2CHRM2
Levomepromazine SCHEMBL27701483 0.83 LMNA (0.88) HTR1AADRA1ADRD3KCNH2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190314385-A1 Process for Preparation of Chlorpromazine or its Pharmaceutically Acceptable Salts SOLARA ACTIVE PHARMA SCIENCES LIMITED (IN) 2019-10-17 US disclosed
EP-3533790-A2 AN IMPROVED PROCESS FOR PREPARATION OF CHLORPROMAZINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS Solara Active Pharma Sciences Limited (IN) 2019-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314385-A1 Process for Preparation of Chlorpromazine or its Pharmaceutically Acceptable Salts CPNE4, CTSZ, CYP3A5 HTR1A 492/4885ADRA1A 162/4885DRD3 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.